224 results on '"Wilding, John P.H."'
Search Results
52. List of Contributors
53. Cardiovascular outcome trials in obesity: A review
54. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
55. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
56. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
57. Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
58. A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
59. Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue by Weight Change, Leptin, Insulin, and Glucose
60. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.
61. Vitamin D receptor ligands attenuate the inflammatory profile of IL-1β-stimulated human white preadipocytes via modulating the NF-κB and unfolded protein response pathways
62. The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency
63. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
64. Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
65. DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
66. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
67. Liraglutide 3.0 mg in obese/overweight adults with or without prediabetes with baseline BMI <35 vs ≥35 kg/m2 in the SCALE Obesity and Prediabetes 56-week randomized, double-blind, placebo-controlled trial
68. Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in individuals with prediabetes and obesity or overweight from the SCALE Obesity and prediabetes randomised, double-blind, placebo-controlled trial
69. Early weight loss responders to liraglutide 3.0 mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years vs early non-responders: SCALE Obesity and Prediabetes
70. Contributors
71. Leptin and the control of obesity
72. Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats
73. Cardiovascular outcome trials in obesity: A review.
74. CAPÍTULO 15 - Metabolismo da glicose e a fisiopatologia do diabetes melito
75. CAPÍTULO 16 - O tratamento clínico do diabetes melito
76. Hospitalization for Heart Failure and Death in New Users of SGLT-2 Inhibitors in Patients With and Without Cardiovascular Disease—CVD Real Study
77. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
78. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.
79. CHAPTER 16 - The clinical management of diabetes mellitus
80. CHAPTER 15 - Glucose metabolism and the pathophysiology of diabetes mellitus
81. Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
82. 127 - Hospitalization for Heart Failure and Death in New Users of SGLT-2 Inhibitors in Patients With and Without Cardiovascular Disease—CVD Real Study
83. Colaboradores
84. Contributors to Davidson's Principles and Practice of Medicine, 22nd Edition
85. CHAPTER 8 - Anti-obesity Drugs: From Animal Models to Clinical Efficacy
86. Risk of Misdiagnosis, Health-Related Quality of Life, and BMI in Patients Who Are Overweight With Doctor-Diagnosed Asthma
87. Facing the Challenges for Europe Research into Action: Liverpool European Congress of Obesity, May 1215, 2013
88. Applied physiology: The control of weight
89. Response: Postprandial Adiponectin Revisited
90. Plasma Adiponectin Increases Postprandially in Obese, but not in Lean, Subjects
91. Obesity and Type-2 Diabetes in the Elderly
92. Contributors
93. Ghrelin: sweet regulation?
94. Applied physiology: the control of weight
95. Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols
96. Hypercalcaemia of hypoadrenal crisis mistaken for hypercalcaemia of malignancy in a patient with known bone metastases: a case report
97. Increases in Neuropeptide Y Content and Gene Expression in the Hypothalamus of Rats Treated with Dexamethasone Are Prevented by Insulin
98. Facing the Challenges for Europe - Research into Action: Liverpool European Congress of Obesity, May 12-15, 2013.
99. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome.
100. The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.